Merck Says US FDA Accepts Supplemental Biologics License Application to Expand Enflonsia's Indication

MT Newswires Live08-06 22:38

Merck (MRK) said Thursday the US Food and Drug Administration has accepted a supplemental biologics license application to expand Enflonsia's indication.

Merck said the application is to expand Enflonsia's indication to include the prevention of respiratory syncytial virus lower respiratory tract disease in children under two years.

The regulator has set a prescription drug user fee act date of March 22, 2027, the company said.

Last month, the European Medicines Agency accepted an application to expand Enflonsia's marketing authorization in the EU for the same population, Merck said.

Price: 128.33, Change: +0.33, Percent Change: +0.26

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment